WO2013164652A3 - Microspheres for treating helicobacter pylori infections - Google Patents

Microspheres for treating helicobacter pylori infections Download PDF

Info

Publication number
WO2013164652A3
WO2013164652A3 PCT/GB2013/051181 GB2013051181W WO2013164652A3 WO 2013164652 A3 WO2013164652 A3 WO 2013164652A3 GB 2013051181 W GB2013051181 W GB 2013051181W WO 2013164652 A3 WO2013164652 A3 WO 2013164652A3
Authority
WO
WIPO (PCT)
Prior art keywords
microspheres
pylori
helicobacter pylori
pylori infections
treating
Prior art date
Application number
PCT/GB2013/051181
Other languages
French (fr)
Other versions
WO2013164652A2 (en
Inventor
Cristina MARTINS
Inês GONÇALVES
Paula GOMES
José Ricardo OLIVEIRA
Celso REIS
Ana MAGALHÃES
Original Assignee
Ineb-Instituto De Engenharia Biomédica
Ipatimup-Institute Of Molecular Pathology And Immunology Of The University Of Porto
Universidade Do Porto
WILSON, Justin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ineb-Instituto De Engenharia Biomédica, Ipatimup-Institute Of Molecular Pathology And Immunology Of The University Of Porto, Universidade Do Porto, WILSON, Justin filed Critical Ineb-Instituto De Engenharia Biomédica
Priority to EP13722013.3A priority Critical patent/EP2844301A2/en
Publication of WO2013164652A2 publication Critical patent/WO2013164652A2/en
Publication of WO2013164652A3 publication Critical patent/WO2013164652A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

There is provided a microsphere for binding H. pylori, wherein the microsphere comprises receptors for H. pylori, and wherein the microspheres and the receptors can bind H. pylori. The microspheres can be used in binding H. pylori bacteria and in treating or preventing H. pylori infection. There is also provided a method of treating or preventing H. pylori infection of the gastric mucosa and/or mucus layer, the method comprising administering an effective amount of microspheres to a patient, wherein the microspheres can bind H. pylori. Pharmaceutical compositions comprising the microspheres are also described.
PCT/GB2013/051181 2012-05-04 2013-05-07 Microspheres WO2013164652A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13722013.3A EP2844301A2 (en) 2012-05-04 2013-05-07 Microspheres for treating helicobacter pylori infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642587P 2012-05-04 2012-05-04
US61/642,587 2012-05-04

Publications (2)

Publication Number Publication Date
WO2013164652A2 WO2013164652A2 (en) 2013-11-07
WO2013164652A3 true WO2013164652A3 (en) 2014-01-09

Family

ID=48428495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/051181 WO2013164652A2 (en) 2012-05-04 2013-05-07 Microspheres

Country Status (2)

Country Link
EP (1) EP2844301A2 (en)
WO (1) WO2013164652A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016108774A1 (en) 2014-12-31 2016-07-07 Izmir Teknoloji Gelistirme Bolgesi A. S. Essential oil loaded mucoadhesive nanocomposite delivery system for gastrointestinal system
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043751A1 (en) * 1999-12-15 2001-06-21 A+ Science Invest Ab Novel helicobacter pylori-binding substances and use thereof
WO2004002495A1 (en) * 2002-06-28 2004-01-08 Glykos Finland Oy Therapeutic compositions for use in prophylaxis or treatment of diarrheas
WO2008071851A1 (en) * 2006-12-13 2008-06-19 Glykos Finland Oy Polyvalent bioconjugates
EP2082750A1 (en) * 2006-09-05 2009-07-29 Chongqing Kang Wei Biotechnology Co., Ltd. Oral recombinant helicobacter pylori vaccine and preparing method thereof
EP2270028A1 (en) * 2008-02-21 2011-01-05 National University Corporation Hokkaido University Biomolecule-immobilized carrier and method for immobilizing biomolecule on carrier

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US8025880B2 (en) 2007-03-01 2011-09-27 Helicure Ab Immunoglobulin against Helicobacter pylori

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043751A1 (en) * 1999-12-15 2001-06-21 A+ Science Invest Ab Novel helicobacter pylori-binding substances and use thereof
WO2004002495A1 (en) * 2002-06-28 2004-01-08 Glykos Finland Oy Therapeutic compositions for use in prophylaxis or treatment of diarrheas
EP2082750A1 (en) * 2006-09-05 2009-07-29 Chongqing Kang Wei Biotechnology Co., Ltd. Oral recombinant helicobacter pylori vaccine and preparing method thereof
WO2008071851A1 (en) * 2006-12-13 2008-06-19 Glykos Finland Oy Polyvalent bioconjugates
EP2270028A1 (en) * 2008-02-21 2011-01-05 National University Corporation Hokkaido University Biomolecule-immobilized carrier and method for immobilizing biomolecule on carrier

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. WADA ET AL: "Direct binding of gangliosides to Helicobacter pylori vacuolating cytotoxin (VacA) neutralizes its toxin activity", GLYCOBIOLOGY, vol. 20, no. 6, 28 January 2010 (2010-01-28), pages 668 - 678, XP055088832, ISSN: 0959-6658, DOI: 10.1093/glycob/cwq014 *
HEJAZI R ET AL: "Stomach-specific anti-H. pylori therapy. Part III: Effect of chitosan microspheres crosslinking on the gastric residence and local tetracycline concentrations in fasted gerbils", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 272, no. 1-2, 19 March 2004 (2004-03-19), pages 99 - 108, XP002460627, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2003.12.001 *
JUSTINE YOUNSON ET AL: "A Human Domain Antibody and Lewis b Glycoconjugate That Inhibit Binding of Helicobacter pylori to Lewis b Receptor and Adhesion to Human Gastric Epithelium", THE JOURNAL OF INFECTIOUS DISEASES, vol. 200, no. 10, 15 November 2009 (2009-11-15), pages 1574 - 1582, XP055088864, ISSN: 0022-1899, DOI: 10.1086/644596 *
KIM S Y ET AL: "Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(d,l-lactide-co-glycolide) microparticles", VACCINE, vol. 17, no. 6, 1 February 1999 (1999-02-01), pages 607 - 616, XP004153820, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(98)00241-2 *
O'MAHONY R ET AL: "Comparison of image analysis software packages in the assessment of adhesion of microorganisms to mucosal epithelium using confocal laser scanning microscopy", JOURNAL OF MICROBIOLOGICAL METHODS, vol. 61, no. 1, 1 April 2005 (2005-04-01), pages 105 - 126, XP027746375, ISSN: 0167-7012, [retrieved on 20050401] *
UMAMAHESWARI R B ET AL: "Site-specific drug delivery of acetohydroxamic acid for the treatment of H. pylori", S.T.P. PHARMA SCIENCES, vol. 13, no. 1, 2003, pages 41 - 48, XP008165834, ISSN: 1157-1489 *

Also Published As

Publication number Publication date
WO2013164652A2 (en) 2013-11-07
EP2844301A2 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
NZ606765A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2010089128A3 (en) Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2011088120A8 (en) Antibody formulation and therapeutic regimens
EP3904502A3 (en) Compositions and methods
WO2012143787A8 (en) Composition comprising probiotic bacteria capable of restoring the barrier effect of the stomach which is lost during pharmacological treatment of gastric hyperacidity
WO2014031610A8 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2011019617A3 (en) Vitamin d3 and analogs thereof for treating alopecia
MX2013003635A (en) N-heteroaryl compounds.
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
SG10201502583VA (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2015038552A3 (en) Aspirin formulation for increased efficacy
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
WO2011037411A3 (en) Composition comprising s-allyl-l-cysteine as active ingredient for preventing or treating gastrointestinal disorders
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
WO2012040082A3 (en) Antidiabetic solid pharmaceutical compositions
WO2009115509A3 (en) Antigenic protein fragments of streptococcus pneumoniae

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2013722013

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13722013

Country of ref document: EP

Kind code of ref document: A2